Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: First results of the phase III EORTC 20012 intergroup trial

Journal of Clinical Oncology

Volumn 34, Issue 17, 2016, Pages 2028-2036

  Carde, Patrice ^a   Karrasch, Matthias ⁱ   Fortpied, Catherine ⁱ   Brice, Pauline ^b   Khaled, Hussein ^j   Casasnovas, Olivier ^c   Caillot, Denis ^c   Gaillard, Isabelle ^d   Bologna, Serge ^e   Ferme, Christophe ^a   Lugtenburg, Pieternella Johanna ^k   Morschhauser, Frank ^f   Aurer, Igor ^l   Coiffier, Bertrand ^g   Meyer, Ralph ^m   Seftel, Matthew ⁿ   Wolf, Max ^o   Glimelius, Bengt ^p   Sureda, Anna ^q   Mounier, Nicolas ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ EORTC DATA CENTER   (Belgium)

^j NATIONAL CANCER INSTITUTE   (Egypt)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l KBC Zagreb   (Croatia)

^m JURAVINSKI CANCER CENTRE   (Canada)

ⁿ CANCERCARE MANITOBA   (Canada)

^o PETER MACCALLUM CANCER CENTRE   (Australia)

^p UPPSALA UNIVERSITY   (Sweden)

^q HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; COUGHING; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG FATALITY; DYSPNEA; EDEMA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; RISK FACTORS; VINBLASTINE; VINCRISTINE;

EID: 84971633002     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.5648     Document Type: Article

References (46)

1. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22:2835-2841, 2004
2. Longo DL: Treatment of advanced Hodgkin lymphoma: The more things change, the more they stay the same. J Clin Oncol 31:660-662, 2013
3. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
4. Chisesi T, Federico M, Levis A, et al: ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: Results of a randomised trial. Ann Oncol 13:102-106, 2002
5. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21: 607-614, 2003
6. Gobbi PG, Levis A, Chisesi T, et al: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediateand advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207, 2005
7. Gordon LI, Hong F, Fisher RI, et al: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31:684-691, 2013
8. Johnson PW, Radford JA, Cullen MH, et al: Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 23:9208-9218, 2005
9. Carde P, MacKintosh FR, Rosenberg SA: A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1:146-153, 1983
10. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
11. Diehl V, Franklin J, Hasenclever D, et al: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16:3810-3821, 1998
12. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
13. Hasenclever D, Brosteanu O, Gerike T, et al: Modelling of chemotherapy: The effective dose approach. Ann Hematol 80:B89-B94, 2001
14. Engert A, Diehl V, Franklin J, et al: Escalateddose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
15. Borchmann P, Haverkamp H, Diehl V, et al: Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29:4234-4242, 2011
16. Diehl V: Advanced Hodgkin's disease: ABVD is better, yet is not good enough! J Clin Oncol 21:583-585, 2003
17. Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, openlabel, phase 3 non-inferiority trial. Lancet 379:1791-1799, 2012
18. Aleman BM, Raemaekers JM, Tirelli U, et al: Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348:2396-2406, 2003
19. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
20. Carde P: The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: Overweight which side? J Clin Oncol 23:9058-9062, 2005
21. Horning SJ: Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program 197-203, 2007
22. Carde P, Cavalli F, Diehl V: Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? Hematol J 1:282-290, 2000
23. Cheson BD: Is BEACOPP better than ABVD? Curr Hematol Malig Rep 2:161-166, 2007
24. Federico M, Luminari S, Iannitto E, et al: ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 27:805-811, 2009
25. Viviani S, Zinzani PL, Rambaldi A, et al: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365:203-212, 2011
26. Skoetz N, Trelle S, Rancea M, et al: Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: A systematic review and network meta-analysis. Lancet Oncol 14:943-952, 2013
27. Federico M, Bellei M, Cheson BD: BEACOPP or no BEACOPP? Lancet Oncol 14:e487-e488, 2013
28. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244, 1999
29. Wang SK, Tsiatis AA: Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 43:193-199, 1987
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
32. Fermé C, Mounier N, Casasnovas O, et al: Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 107:4636-4642, 2006
33. Dose escalated BEACOPP chemotherapy improves failure-free survival in advanced Hodgkin's disease: Updated results of the German Hodgkin's Lymphoma Study Group. Presented at the 42nd ASH Annual Meeting and Exposition, San Francisco, CA, December 1-5, 2000
34. Wongso D, Fuchs M, Plütschow A, et al: Treatment-related mortality in patients with advancedstage Hodgkin lymphoma: An analysis of the German Hodgkin Study Group. J Clin Oncol 31:2819-2824, 2013
35. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007
36. Ghalibafian M, Beaudre A, Girinsky T: Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: Dose constraints to virtual volumes or to organs at risk? Radiother Oncol 87:82-88, 2008
37. Eichenauer DA, Thielen I, Haverkamp H, et al: Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood 123:1658-1664, 2014
38. Merli F, Luminari S, Mammi C, et al: Longterm follow-up analysis of HD2000 trial comparing ABVD versus BEACOPP versus COPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin lymphoma: A study from the Fondazione Italiana Linfomi. 56th ASH Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014 (abstr 499)
39. Behringer K, Breuer K, Reineke T, et al: Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 23:7555-7564, 2005
40. Carde P: Risks of infertility and early menopause from anticancer and immunosuppressive programs: Methods of fertility preservation and palliation. Am Soc Clin Oncol Ed Book, 400-417, 2004
41. Jurczak W, Krochmalczyk D, Pabian W, et al: Quality of life and fertility in Hodgkin disease patients treated with escalated BEACOPP. Haematologica 94, 2009 (abstr 89)
42. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapyradiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
43. Sieniawski M, Reineke T, Nogova L, et al: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: A report of the German Hodgkin Study Group (GHSG). Blood 111:71-76, 2008
44. Mounier N, Brice P, Bologna S, et al: ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 25:1622-1628, 2014
45. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002
46. Sureda A, Robinson S, Canals C, et al: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:455-462, 2008